PRODUCT

PNC-27 (30 mg Vial)

No short description available.

Quickstart Highlights

PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.
Typical daily range: 100–500 mcg once daily (gradual titration).
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Reconstitution

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Protocol Overview

Goal:Educational exploration of a p53‑derived peptide studied preclinically for selective cancer‑cell membrane disruption[1][2].
Schedule:Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range:100–500 mcg daily with gradual titration.
Reconstitution:3.0 mL per 30 mg vial (10 mg/mL) for simplified unit measurements.
Storage:Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosage Protocols

Start:100 mcg daily for 1–2 weeks; increase by ~100 mcg every 2 weeks as tolerated.
Target:300–500 mcg daily by Weeks 5–16.
Frequency:Once per day (subcutaneous).
Cycle Length:8–12 weeks; optional extension to 16 weeks.
Timing:Any consistent time; rotate injection sites.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; short‑term refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
Regulatory Warning: PNC-27 has no FDA approval and no established human safety data[3]. This information is strictly educational.

How It Works

PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence[1]. Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells[2][6]. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration[4]. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.

Lifestyle Factors

Maintain a balanced, nutrient‑dense diet to support overall metabolic function.
Prioritize adequate sleep and stress management for immune and recovery support.
Consult qualified healthcare professionals before any experimental peptide use.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8].
Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[10].

Benefits and Side Effects

Benefits

Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 while sparing normal cells[2][6].
Mechanism involves direct membrane lysis rather than apoptosis in affected cells[7].
No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established[3].

Side Effects

Possible injection‑site reactions (redness, irritation) may occur with subcutaneous administration.

PNC-27 (30 mg Vial)

Resources

Categories

Company